


32. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula I.
33. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula II.
34. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula III.
35. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IV.
36. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula V.
37. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VI.
38. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VII.
39. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VIII.
40. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IX.
41. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula X.

42. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XI.
43. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XII.
44. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIII.
45. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIV.
46. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XV.
47. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVI.
48. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVII.
49. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVIII.
50. (Amended) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIX.--


Please add new claim 51:

--51. The method of claim 20, wherein the ecto-phosphatase inhibitory molecule is selected from the group consisting of molecules having the Formulae I through XIX:


I




II




III




IV




V




VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI




XVII



XVIII



XIX



2.0 REMARKS

Claims 20 and 32-50 have been amended herein and new claim 51 has been added. The claims were previously amended in a Preliminary Amendment mailed concurrently with the filing of the instant case. The amendments do not add new matter to the case. The amendments further do not narrow the claims and accordingly Applicants do not intent to disclaim any subject matter through the amendment.

A marked-up copy of the claim amendments is attached herewith as Appendix A. Claims 20-21 and 25-51 are now pending in the case and presented for consideration. A clean copy of the pending claims following entry of the instant amendment is attached as Appendix B. The Commissioner is authorized to withdraw any fees due in connection with the filing of the instant

paper from Fulbright & Jaworski L.L.P. Deposit Account No. 50-1212/10110234/RH10056.


Please date stamp and return the enclosed postcard to evidence receipt of this document.

3.0 CONCLUSION

In conclusion, Applicant submits that, in light of the foregoing remarks, the present case is in condition for allowance and such favorable action is respectfully requested. If however, some unanswered questions remain in the mind of the Examiner, or if the Examiner would be available to discuss the merits of this case, and assist in facilitating its speedy allowance, the Examiner is invited to contact the Applicant's undersigned representative at (512)536-3085 with any questions, comments or suggestions relating to the referenced patent application.

Consideration of the foregoing remarks is earnestly solicited by the Applicant.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants


FULBRIGHT & JAWORSKI, L.L.P.
600 Congress Ave., Ste. 1900
Austin, Texas 78701
(512) 474-5201

Date: April 25, 2002


APPENDIX A: VERSION OF CLAIM AMENDMENTS MARKED TO SHOW CHANGES

20. (Twice Amended) A method for decreasing drug resistance in a target bacteria, yeast, plant or mammalian cell comprising introducing to the cell a drug resistance-inhibiting amount of an ecto-phosphatase inhibitory molecule, [selected from the group consisting of molecules having the Formulae I through XIX:


I




II




III




IV




V




VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI




XVII



XVIII



XIX



]

32. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula I.

33. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula II.

34. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula III.

35. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IV.

36. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula V.

37. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VI.

38. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VII.

39. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VIII.

40. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IX.

41. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula X.

42. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XI.

43. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XII.

44. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIII.

45. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIV.

46. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XV.

47. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVI.

48. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVII.

49. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVIII.

50. (Amended) The method of claim [20] 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIX.

**APPENDIX B: CLEAN COPY OF PENDING CLAIMS FOLLOWING ENTRY OF THE
INSTANT PRELIMINARY AMENDMENT**

20. A method for decreasing drug resistance in a target bacteria, yeast, plant or mammalian cell comprising introducing to the cell a drug resistance-inhibiting amount of an ecto-phosphatase inhibitory molecule.
21. The method according to claim 20 wherein the mammalian cell is a tumor cell.
25. The method of claim 20, further comprising down-regulating an ABC transporter in said cell.
26. The method of claim 20, wherein said ecto-phosphatase is selected from the group consisting of *Pisum sativum* apyrase and *Homo sapiens* apyrase.
27. The method of claim 25, wherein the ABC transporter is selected from the group consisting of *Arabidopsis thaliana* AtPGP-1, *Homo sapiens* Pgp, *Homo sapiens* MDR- β , *Saccharomyces cerevisiae* STS1, *Saccharomyces cerevisiae* Pdr5p, *Aspergillus fumigatus* Afu-MDR1 and *Lactococcus lactis* LmrA.
28. The method of claim 20, wherein the cell is a bacteria cell.
29. The method of claim 20, wherein the cell is a yeast cell.
30. The method of claim 20, wherein the cell is a plant cell.
31. The method of claim 20, wherein the cell is a mammalian cell.
32. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula I.

33. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula II.

34. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula III.

35. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IV.

36. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula V.

37. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VI.

38. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VII.


39. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VIII.

40. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IX.

41. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula X.

42. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XI.


43. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XII.
44. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIII.
45. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIV.
46. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XV.
47. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVI.
48. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVII.
49. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVIII.
50. The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIX.
51. The method of claim 20, wherein the ecto-phosphatase inhibitory molecule is selected from the group consisting of molecules having the Formulae I through XIX:

CCCCCN1C(=S)C(=N1[N+](=O)[O-])c2ccccc2


Chemical structure of 4-(4-methylphenyl)benzenesulfonamide (4-Toluenesulfonamide). It consists of a benzene ring substituted with a methyl group and a sulfonamide group (-SO₂NH-), which is further connected to another benzene ring.

CCN(CC)C1=CN(S(=O)(=O)Nc2ccccc2)C(=N1)Nc3ccccc3


IV




V




VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI



XVII



XVIII



XIX

